annex 2 country profiles

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "annex 2 country profiles"

Transcription

1 Annex 2 Country profiles

2

3 Afghanistan High TB burden Estimates of TB burden a 213 Rate (per 1 population) 13 (8.4 16) 42 (27 53) Mortality (HIV+TB only).82 (.65.1).27 (.21.33) (includes HIV+TB) 1 (54 17) 34 ( ) (includes HIV+TB) 58 (51 65) 189 ( ) (HIV+TB only).2 (.17.22).64 (.57.72) Case detection, all forms (%) 53 (47 6) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 3.7 ( ) 2 (13 27) pulmonary TB cases 82 (56 1 1) 46 (3 61) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed 8 2 Extrapulmonary 7 56 Total new and relapse 3 57 Previously treated, excluding relapses Total cases notified Among 3 57 new and relapse cases: (11%) cases aged under 15 years; male:female ratio:.7 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 7 (<1%) 38 (2%) 45 Laboratory-confirmed RR-/MDR-TB cases 73 Patients started on MDR-TB treatment 49 TB/HIV 213 TB patients with known HIV status (26) HIV-positive TB patients 9 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB 1 HIV-positive people provided with IPT 12 and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population) Sites performing Xpert MTB/RIF 1 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 9.5 % Funded domestically 8% % Funded internationally 57% % Unfunded 35% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

4 Bangladesh High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 8 (51 11) 51 (33 69) Mortality (HIV+TB only).16 (.1.24).1 (.7.15) (includes HIV+TB) 63 (33 1 ) 42 (21 656) (includes HIV+TB) 35 (31 4) 224 ( ) (HIV+TB only).41 (.18.46).26 (.12.3) Case detection, all forms (%) 53 (47 59) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.7 2.5) 29 (24 34) pulmonary TB cases 2 1 (1 3 7) 2 6 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 5 51 (3%) cases aged under 15 years; male:female ratio: 1.5 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 446 (<1%) (5%) Laboratory-confirmed RR-/MDR-TB cases 1 24 Patients started on MDR-TB treatment 684 TB/HIV 213 TB patients with known HIV status 2 67 (1) HIV-positive TB patients 68 (3) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 61 (9) HIV-positive TB patients on antiretroviral therapy (ART) 68 (1) HIV-positive people screened for TB 67 HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).7 Culture (per 5 million population) <.1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 26 Yes, in and outside country (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 57 % Funded domestically 5% % Funded internationally 33% % Unfunded 62% Estimates of TB disease burden have not been approved by the national TB programme in Bangladesh and a joint reassessment will be undertaken following the completion of the prevalence survey planned for 215. b Includes cases with unknown previous TB treatment history Global Tuberculosis Report 214 Data for all years can be downloaded from

5 Brazil High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 4.4 ( ) 2.2 ( ) Mortality (HIV+TB only) 2.1 ( ) 1 ( ) (includes HIV+TB) 11 (54 2) 57 (27 99) (includes HIV+TB) 93 (83 11) 46 (41 52) (HIV+TB only) 13 (13 13) 6.5 ( ) Case detection, all forms (%) 82 (72 92) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (1 1.8) 7.5 ( ) pulmonary TB cases 84 (6 1 1) 94 (71 1 2) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse 76 2 Previously treated, excluding relapses 7 29 Total cases notified Among 76 2 new and relapse cases: (3%) cases aged under 15 years; male:female ratio: 2. Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 67 (2%) 217 (2%) 895 Laboratory-confirmed RR-/MDR-TB cases 76 Patients started on MDR-TB treatment 717 TB/HIV 213 TB patients with known HIV status (65) HIV-positive TB patients 9 34 (17) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 1.5 Culture (per 5 million population) 8.6 Drug susceptibility testing (per 5 million population) 1. Sites performing Xpert MTB/RIF Financing TB control 214 National TB programme budget (US$ millions) 79 % Funded domestically 87% % Funded internationally 2% % Unfunded 12% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

6 Cambodia High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 1 (6.3 14) 66 (42 92) Mortality (HIV+TB only).59 (.45.76) 3.9 (3 5) (includes HIV+TB) 11 (91 13) 715 (64 834) (includes HIV+TB) 61 (55 67) 4 ( ) (HIV+TB only) 2.3 ( ) 15 (14 17) Case detection, all forms (%) 62 (56 68) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.7 2.5) 11 (4 22) pulmonary TB cases 32 (16 58) 18 (68 37) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed 9 69 Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 64 (<1%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 338 (2%) (74%) Laboratory-confirmed RR-/MDR-TB cases 121 Patients started on MDR-TB treatment 121 TB/HIV 213 TB patients with known HIV status (82) HIV-positive TB patients (4) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 17 (89) HIV-positive TB patients on antiretroviral therapy (ART) 1 1 (89) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.4 Culture (per 5 million population) 1.3 Drug susceptibility testing (per 5 million population).3 Sites performing Xpert MTB/RIF 1 No Financing TB control 214 National TB programme budget (US$ millions) 31 % Funded domestically 4% % Funded internationally 32% % Unfunded 64% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

7 China High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 41 (4 43) 3 ( ) Mortality (HIV+TB only).67 ( ).5 (.2.1) (includes HIV+TB) 1 3 ( ) 94 (82 17) (includes HIV+TB) 98 (91 1 1) 7 (66 77) (HIV+TB only) 4.5 ( ).33 (.31.72) Case detection, all forms (%) 87 (79 93) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 5.7 (4.5 7) 26 (22 3) pulmonary TB cases 45 (35 55 ) 9 2 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 8 65 Total cases notified Among new and relapse cases: 4 83 (<1%) cases aged under 15 years; male:female ratio: 2.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (11%) (32%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (39) HIV-positive TB patients (1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) (67) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).2 Culture (per 5 million population) 4.6 Drug susceptibility testing (per 5 million population).9 Sites performing Xpert MTB/RIF 16 Financing TB control 214 National TB programme budget (US$ millions) 347 % Funded domestically 78% % Funded internationally 3% % Unfunded 19% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

8 Democratic Republic of the Congo High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 46 (22 53) 68 (33 78) Mortality (HIV+TB only) 6.4 (.17 24) 9.5 (.25 35) (includes HIV+TB) 37 (19 61) 549 ( ) (includes HIV+TB) 22 (2 24) 326 ( ) (HIV+TB only) 16 (9.8 75) 24 (14 111) Case detection, all forms (%) 51 (47 56) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.6 (.1 5.5) 13 (.2 28) pulmonary TB cases 2 2 (9 4 7) 9 (14 2 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 3 86 (4%) cases aged under 15 years; male:female ratio: 1.3 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 344 (<1%) 1 7 (14%) Laboratory-confirmed RR-/MDR-TB cases 272 Patients started on MDR-TB treatment 147 TB/HIV 213 TB patients with known HIV status (44) HIV-positive TB patients (14) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (7) HIV-positive TB patients on antiretroviral therapy (ART) (48) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.3 Culture (per 5 million population).1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 26 Financing TB control 214 National TB programme budget (US$ millions) 66 % Funded domestically 3% % Funded internationally 21% % Unfunded 75% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

9 Ethiopia High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 3 (16 47) 32 (17 5) Mortality (HIV+TB only) 5.6 (3.6 8) 5.9 ( ) (includes HIV+TB) 2 (16 24) 211 (17 257) (includes HIV+TB) 21 (18 26) 224 ( ) (HIV+TB only) 22 (19 32) 24 (21 33) Case detection, all forms (%) 62 (51 74) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.6 (.9 2.8) 12 (5.6 21) pulmonary TB cases 1 4 (8 2 5) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (16%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 212 (<1%) Laboratory-confirmed RR-/MDR-TB cases 558 Patients started on MDR-TB treatment 413 TB/HIV 213 TB patients with known HIV status (71) HIV-positive TB patients (11) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) 7 55 (68) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).4 Drug susceptibility testing (per 5 million population).4 Sites performing Xpert MTB/RIF 23 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 94 % Funded domestically 7% % Funded internationally 3% % Unfunded 63% Estimates of TB disease burden for Ethiopia are provisional pending a joint review by WHO and the MOH in early Data for all years can be downloaded from Global Tuberculosis Report

10 India High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 24 (15 35) 19 (12 28) Mortality (HIV+TB only) 38 (31 44) 3 ( ) (includes HIV+TB) 2 6 ( ) 211 ( ) (includes HIV+TB) 2 1 (2 2 3) 171 ( ) (HIV+TB only) 12 (1 14) 9.7 (8.3 11) Case detection, all forms (%) 58 (54 61) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.2 ( ) 15 (11 19) pulmonary TB cases 2 (17 24 ) 41 (3 52 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (5%) cases aged under 15 years Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (63) HIV-positive TB patients (5) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (95) HIV-positive TB patients on antiretroviral therapy (ART) (88) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1. Culture (per 5 million population).2 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 54 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 252 % Funded domestically 66% % Funded internationally 34% % Unfunded % Estimates for India have not yet been officially approved by the Ministry of Health & Family Welfare, Government of India, and should therefore be considered provisional Global Tuberculosis Report 214 Data for all years can be downloaded from

11 Indonesia High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 64 (36 93) 25 (14 37) Mortality (HIV+TB only) 3.9 ( ) 1.6 ( ) (includes HIV+TB) 68 (34 1 1) 272 (138 45) (includes HIV+TB) 46 (41 52) 183 (164 27) (HIV+TB only) 15 (8.7 2) 5.8 ( ) Case detection, all forms (%) 71 (63 8) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.9 ( ) 12 (8.1 17) pulmonary TB cases 5 7 ( ) 1 1 (77 1 6) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (8%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 53 (<1%) 3 74 (39%) Laboratory-confirmed RR-/MDR-TB cases 912 Patients started on MDR-TB treatment 89 TB/HIV 213 TB patients with known HIV status (2) HIV-positive TB patients (21) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 477 (3) HIV-positive TB patients on antiretroviral therapy (ART) 332 (21) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 2.2 Culture (per 5 million population).4 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 23 Financing TB control 214 National TB programme budget (US$ millions) 127 % Funded domestically 13% % Funded internationally 3% % Unfunded 57% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

12 Kenya High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 9.1 (5.5 12) 2 (12 27) Mortality (HIV+TB only) 9.5 (7.5 12) 21 (17 27) (includes HIV+TB) 13 (69 2) 283 ( ) (includes HIV+TB) 12 (12 12) 268 ( ) (HIV+TB only) 48 (47 5) 19 (15 112) Case detection, all forms (%) 75 (74 77) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.6 (.1 5.5) 13 (.2 28) pulmonary TB cases 1 7 (7 3 7) 1 1 (17 2 3) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (6%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 127 (<1%) (22%) Laboratory-confirmed RR-/MDR-TB cases 16 Patients started on MDR-TB treatment 29 TB/HIV 213 TB patients with known HIV status (94) HIV-positive TB patients (38) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (99) HIV-positive TB patients on antiretroviral therapy (ART) (84) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 4.2 Culture (per 5 million population).8 Drug susceptibility testing (per 5 million population).7 Sites performing Xpert MTB/RIF 21 No Financing TB control 214 National TB programme budget (US$ millions) 57 % Funded domestically 23% % Funded internationally 17% % Unfunded 6% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

13 Mozambique High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 18 (9.4 26) 69 (36 11) Mortality (HIV+TB only) 38 (27 51) 148 (15 198) (includes HIV+TB) 14 (78 23) 559 (33 893) (includes HIV+TB) 14 (11 18) 552 (442 68) (HIV+TB only) 81 (64 1) 312 ( ) Case detection, all forms (%) 37 (3 47) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 3.5 ( ) 11 ( 25) pulmonary TB cases 1 5 (95 2 1) 83 ( 1 9) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 634 (3%) 653 (9%) Laboratory-confirmed RR-/MDR-TB cases 444 Patients started on MDR-TB treatment 313 TB/HIV 213 TB patients with known HIV status (91) HIV-positive TB patients (56) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (97) HIV-positive TB patients on antiretroviral therapy (ART) (72) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in 212 HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.3 Culture (per 5 million population).6 Drug susceptibility testing (per 5 million population).4 Sites performing Xpert MTB/RIF 14 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 19 % Funded domestically % Funded internationally 22% % Unfunded 78% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

14 Myanmar High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 26 (16 38) 49 (29 71) Mortality (HIV+TB only) 4.3 ( ) 8 ( ) (includes HIV+TB) 25 (19 32) 473 ( ) (includes HIV+TB) 2 (18 22) 373 (34 413) (HIV+TB only) 17 (16 18) 33 (3 34) Case detection, all forms (%) 68 (61 74) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 5 ( ) 27 (15 39) pulmonary TB cases 5 7 ( ) 3 3 ( ) TB case notifications 213 b c (rate per 1 population per year) (rate per 1 population) Population million Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 7 37 Total cases notified Reported cases of RR-/MDR-TB 213 Total c Cases tested for RR-/MDR-TB (13%) (7%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment 667 TB/HIV 213 TB patients with known HIV status (12) HIV-positive TB patients (32) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (89) HIV-positive TB patients on antiretroviral therapy (ART) (74) HIV-positive people screened for TB HIV-positive people provided with IPT 468 cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population).9 Culture (per 5 million population).3 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 24 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 36 % Funded domestically 15% % Funded internationally 49% % Unfunded 35% b Case notifications were updated after TB burden estimates had already been produced. c Includes cases with unknown previous TB treatment history. (rate per 1 population per year) Notified (new and relapse) (HIV+TB only) HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

15 Nigeria High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 16 (68 27) 94 (39 156) Mortality (HIV+TB only) 85 (47 14) 49 (27 78) (includes HIV+TB) 57 (43 73) 326 ( ) (includes HIV+TB) 59 (34 88) 338 (194 56) (HIV+TB only) 14 (81 22) 81 (47 124) Case detection, all forms (%) 16 (11 28) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2.9 (2.1 4) 14 (1 19) pulmonary TB cases 2 5 ( ) 1 2 (86 1 6) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified 1 41 Among 1 41 new and relapse cases: (6%) cases aged under 15 years; male:female ratio: 1.5 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 1 41 Laboratory-confirmed RR-/MDR-TB cases 669 Patients started on MDR-TB treatment 426 TB/HIV 213 TB patients with known HIV status (88) HIV-positive TB patients (22) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (87) HIV-positive TB patients on antiretroviral therapy (ART) (67) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population).9 Culture (per 5 million population).1 Drug susceptibility testing (per 5 million population) <.1 Sites performing Xpert MTB/RIF 49 Yes, outside country Financing TB control 214 National TB programme budget (US$ millions) 139 % Funded domestically 9% % Funded internationally 38% % Unfunded 53% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

16 Pakistan High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 1 (45 17) 56 (25 92) Mortality (HIV+TB only).97 ( ).53 (.28.86) (includes HIV+TB) 62 (52 74) 342 (284 46) (includes HIV+TB) 5 (37 65) 275 (25 357) (HIV+TB only) 2.6 ( ) 1.4 ( ) Case detection, all forms (%) 58 (44 78) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 4.3 ( ) 19 (14 25) pulmonary TB cases 9 9 ( ) 3 1 (2 2 4 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (1%) cases aged under 15 years; male:female ratio: 1. Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (5%) 3 51 (22%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status 8 36 (3) HIV-positive TB patients 36 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT cases registered in Previously treated cases registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).8 Culture (per 5 million population).3 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 32 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) 1 5 Population million Notified (new and relapse) (HIV+TB only) HIV-positive Financing TB control 214 National TB programme budget (US$ millions) 114 % Funded domestically % Funded internationally 3% % Unfunded 7% Global Tuberculosis Report 214 Data for all years can be downloaded from

17 Philippines High TB burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 27 (25 29) 27 (25 29) Mortality (HIV+TB only).58 (.42.77).6 (.4.8) (includes HIV+TB) 43 (38 49) 438 ( ) (includes HIV+TB) 29 (26 33) 292 ( ) (HIV+TB only).31 (.18.34).32 (.18.35) Case detection, all forms (%) 8 (71 9) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2 ( ) 21 (16 29) pulmonary TB cases 4 4 (3 1 6 ) 4 1 (3 5 5) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: 2 65 (2%) cases aged under 15 years; male:female ratio: 2.3 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (3%) (7%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status 5 34 (2) HIV-positive TB patients 26 (<1) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB 3 6 HIV-positive people provided with IPT cases registered in Previously treated cases registered in 212 HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population) 2.6 Culture (per 5 million population).9 Drug susceptibility testing (per 5 million population).2 Sites performing Xpert MTB/RIF 16 Financing TB control 214 National TB programme budget (US$ millions) 117 % Funded domestically 27% % Funded internationally 25% % Unfunded 48% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) J Population million Notified (new and relapse) (HIV+TB only) HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

18 Russian Federation High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 17 (17 18) 12 (12 13) Mortality (HIV+TB only) 1.4 (1 1.9).98 (.7 1.3) (includes HIV+TB) 16 (74 29) 114 (51 21) (includes HIV+TB) 13 (12 14) 89 (82 1) (HIV+TB only) 7.9 ( ) 5.5 ( ) Case detection, all forms (%) 83 (74 91) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 19 (14 25) 49 (4 59) pulmonary TB cases 16 (11 2 ) 25 (2 3 ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (4%) cases aged under 15 years; male:female ratio: 2.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (84%) (23%) Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status c HIV-positive TB patients 4 99 HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) HIV-positive TB patients on antiretroviral therapy (ART) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 3.7 Culture (per 5 million population) 11.6 Drug susceptibility testing (per 5 million population) 7.6 Sites performing Xpert MTB/RIF 72 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Financing TB control 214 National TB programme budget (US$ millions) % Funded domestically 1% % Funded internationally % Unfunded % c The reported number of TB patients with known HIV status is for new TB patients in the civilian sector only. It was not possible to calculate the percentage of all TB patients with known HIV status Global Tuberculosis Report 214 Data for all years can be downloaded from

19 South Africa High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 25 (15 38) 48 (28 73) Mortality (HIV+TB only) 64 (47 83) 121 (9 158) (includes HIV+TB) 38 (21 59) 715 ( ) (includes HIV+TB) 45 (41 52) 86 (776 98) (HIV+TB only) 27 (24 31) 52 ( ) Case detection, all forms (%) 69 (6 76) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.8 ( ) 6.7 ( ) pulmonary TB cases 4 6 ( ) 2 2 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new and relapse cases: (12%) cases aged under 15 years; male:female ratio: 1.2 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB Laboratory-confirmed RR-/MDR-TB cases Patients started on MDR-TB treatment TB/HIV 213 TB patients with known HIV status (9) HIV-positive TB patients (62) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (81) HIV-positive TB patients on antiretroviral therapy (ART) (66) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in Laboratories 213 Smear (per 1 population).4 Culture (per 5 million population) 1.4 Drug susceptibility testing (per 5 million population) 1.4 Sites performing Xpert MTB/RIF 27 Financing TB control 214 National TB programme budget (US$ millions) 162 % Funded domestically 84% % Funded internationally 16% % Unfunded % (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

20 Thailand High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 8.1 (4.9 12) 12 (7.3 18) Mortality (HIV+TB only) 1.9 ( ) 2.8 (2 3.6) (includes HIV+TB) 1 (48 17) 149 (72 252) (includes HIV+TB) 8 (71 9) 119 (16 134) (HIV+TB only) 12 (1 13) 17 (15 19) Case detection, all forms (%) 8 (71 89) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 2 ( ) 19 (14 25) pulmonary TB cases 1 (73 1 5) 88 (64 1 2) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (1%) 54 (12%) Laboratory-confirmed RR-/MDR-TB cases 23 Patients started on MDR-TB treatment 23 TB/HIV 213 TB patients with known HIV status (83) HIV-positive TB patients (15) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 26 (63) HIV-positive TB patients on antiretroviral therapy (ART) 4 89 (59) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in 211 XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.6 Culture (per 5 million population) 4.8 Drug susceptibility testing (per 5 million population) 1.3 Sites performing Xpert MTB/RIF 14 (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) Financing TB control 214 National TB programme budget (US$ millions) 16 c % Funded domestically 54% % Funded internationally 33% % Unfunded 13% c Data reported are only national level budgets for the Bureau of TB and the National Health Security Office, and do not include provincial, local and private sector budgets and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

21 Uganda High TB burden High HIV burden Estimates of TB burden a 213 Rate (per 1 population) 4.1 ( ) 11 (5.8 18) Mortality (HIV+TB only) 7.2 (5 9.9) 19 (13 26) (includes HIV+TB) 58 (32 91) 154 (85 243) (includes HIV+TB) 62 (56 73) 166 ( ) (HIV+TB only) 32 (29 38) 86 (77 12) Case detection, all forms (%) 73 (63 81) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.4 (.6 2.2) 12 (6.8 19) pulmonary TB cases 54 (23 84) 49 (27 78) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 2 11 Total cases notified Among new cases: 649 (3%) cases aged under 15 years; male:female ratio: 1.9 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 92 (<1%) 397 (1%) 549 Laboratory-confirmed RR-/MDR-TB cases 117 Patients started on MDR-TB treatment 199 TB/HIV 213 TB patients with known HIV status (91) HIV-positive TB patients (48) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (96) HIV-positive TB patients on antiretroviral therapy (ART) (65) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in 212 RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 3.5 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population).5 Sites performing Xpert MTB/RIF 37 Financing TB control 214 National TB programme budget (US$ millions) 39 % Funded domestically 5% % Funded internationally 14% % Unfunded 81% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

22 United Republic of Tanzania High TB burden High HIV burden High MDR-TB BUrden Estimates of TB burden a 213 Rate (per 1 population) 6 ( ) 12 (7 17) Mortality (HIV+TB only) 6.1 ( ) 12 (9.8 15) (includes HIV+TB) 85 (45 14) 172 (92 277) (includes HIV+TB) 81 (77 84) 164 (157 17) (HIV+TB only) 3 (29 31) 61 (58 63) Case detection, all forms (%) 79 (77 83) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 1.1 (.5 2) 3.1 (.9 7.9) pulmonary TB cases 53 (24 96) 86 (25 22) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses Total cases notified Among new cases: (11%) cases aged under 15 years; male:female ratio: 1.4 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB (5%) 728 (26%) 2 2 Laboratory-confirmed RR-/MDR-TB cases 64 Patients started on MDR-TB treatment 28 TB/HIV 213 TB patients with known HIV status (83) HIV-positive TB patients 2 32 (37) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) (98) HIV-positive TB patients on antiretroviral therapy (ART) (73) HIV-positive people screened for TB HIV-positive people provided with IPT 166 and relapse cases registered in Previously treated cases, excluding relapse, registered in HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.9 Culture (per 5 million population).5 Drug susceptibility testing (per 5 million population).1 Sites performing Xpert MTB/RIF 35 Financing TB control 214 National TB programme budget (US$ millions) 61 % Funded domestically 13% % Funded internationally 17% % Unfunded 69% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) J 8 J and relapse excluding relapse HIV-positive Global Tuberculosis Report 214 Data for all years can be downloaded from

23 Viet Nam High TB burden High HIV burden High MDR-TB burden Estimates of TB burden a 213 Rate (per 1 population) 17 (12 24) 19 (13 26) Mortality (HIV+TB only) 2 ( ) 2.1 ( ) (includes HIV+TB) 19 (79 35) 29 (86 384) (includes HIV+TB) 13 (11 16) 144 ( ) (HIV+TB only) 9.4 (8 12) 1 (8.7 13) Case detection, all forms (%) 76 (63 91) Estimates of MDR-TB burden a 213 % of TB cases with MDR-TB 4 ( ) 23 (17 3) pulmonary TB cases 3 ( ) 2 1 ( ) TB case notifications 213 b Pulmonary, bacteriologically confirmed Pulmonary, clinically diagnosed Extrapulmonary Total new and relapse Previously treated, excluding relapses 1 81 Total cases notified Among 5 67 new cases: 143 (<1%) cases aged under 15 years; male:female ratio: 2.9 Reported cases of RR-/MDR-TB 213 Total b Cases tested for RR-/MDR-TB 353 (<1%) (45%) Laboratory-confirmed RR-/MDR-TB cases 1 24 Patients started on MDR-TB treatment 948 TB/HIV 213 TB patients with known HIV status (7) HIV-positive TB patients (6) HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 25 (72) HIV-positive TB patients on antiretroviral therapy (ART) (61) HIV-positive people screened for TB HIV-positive people provided with IPT and relapse cases registered in Previously treated cases, excluding relapse, registered in 212 HIV-positive TB cases, all types, registered in RR-/MDR-TB cases started on second-line treatment in XDR-TB cases started on second-line treatment in 211 Laboratories 213 Smear (per 1 population) 1.1 Culture (per 5 million population) 1.3 Drug susceptibility testing (per 5 million population).1 Sites performing Xpert MTB/RIF 27 Financing TB control 214 National TB programme budget (US$ millions) 73 % Funded domestically 9% % Funded internationally 18% % Unfunded 73% (rate per 1 population per year) (rate per 1 population) (rate per 1 population per year) Population million Notified (new and relapse) (HIV+TB only) and relapse excluding relapse HIV-positive Data for all years can be downloaded from Global Tuberculosis Report

Lao PDR TB control program and. Migrant Populations

Lao PDR TB control program and. Migrant Populations Lao PDR TB control program and Migrant Populations National TB Centre (NTC), Vientiane Forum on international migration and health in Thailand: Status and Challenges to controlling TB", Bangkok, 4-6 June

More information

Drug-resistant Tuberculosis

Drug-resistant Tuberculosis page 1/6 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Context - Tuberculosis (TB) is an infectious disease that affects a growing number of

More information

Tuberculosis in Myanmar Progress, Plans and Challenges

Tuberculosis in Myanmar Progress, Plans and Challenges Tuberculosis in Myanmar Progress, Plans and Challenges Myanmar is one of the world s 22 high tuberculosis (TB) burden countries, with a TB prevalence rate three times higher than the global average and

More information

JOINT TUBERCULOSIS AND HIV PROGRAMMING INFORMATION NOTE

JOINT TUBERCULOSIS AND HIV PROGRAMMING INFORMATION NOTE JOINT TUBERCULOSIS AND HIV PROGRAMMING INFORMATION NOTE April 2014 This document has been prepared by the Global Fund Interagency Working Group on TB/HIV. Member organizations of the Working Group include

More information

Goal 6: Combat HIV/AIDS, Malaria, and Other Diseases

Goal 6: Combat HIV/AIDS, Malaria, and Other Diseases 113 The large majority of HIV sufferers live in just six countries. Adult HIV victims in the region are mainly men. In Lao People s Democratic Republic (Lao PDR), over 90% of those living with HIV have

More information

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme

More information

Manual on use of routine data quality assessment (RDQA) tool for TB monitoring. World Health Organization Stop TB Department, Geneva

Manual on use of routine data quality assessment (RDQA) tool for TB monitoring. World Health Organization Stop TB Department, Geneva Manual on use of routine data quality assessment (RDQA) tool for TB monitoring World Health Organization Stop TB Department, Geneva WHO Library Cataloguing in Publication Data Manual on use of routine

More information

Module 3 TREATMENT OF CHILDHOOD TB

Module 3 TREATMENT OF CHILDHOOD TB Module 3 TREATMENT OF CHILDHOOD TB Burden of TB in children Tuberculosis (TB) in children is common wherever TB is common in adults i.e. TB endemic settings TB is an important cause of illness and death

More information

World Population to reach 10 billion by 2100 if Fertility in all Countries Converges to Replacement Level

World Population to reach 10 billion by 2100 if Fertility in all Countries Converges to Replacement Level UNITED NATIONS PRESS RELEASE EMBARGOED UNTIL 3 MAY 2011, 11:00 A.M., NEW YORK TIME World Population to reach 10 billion by if Fertility in all Countries Converges to Replacement Level UNITED NATIONS, 3

More information

Global Fund Country Allocations:

Global Fund Country Allocations: Global Fund Country Allocations: 2014-2016 12 March 2014 In 2014, the Global Fund is implementing a new funding model. As partners in the response to HIV, tuberculosis and malaria, we expect to reach more

More information

Kenya Joint TB/HIV Concept Note Development

Kenya Joint TB/HIV Concept Note Development Kenya Joint TB/HIV Concept Note Development Market Place Presentation Outline Introduction TB HIV NFM goals, objectives and indicators TB HIV CN allocation Kenya joint TB HIV programming TB HIV actors

More information

Goal 6: Combat HIV/AIDS, Malaria, and Other Diseases

Goal 6: Combat HIV/AIDS, Malaria, and Other Diseases 87 In most economies for which data are available, less than 1% of the population is reported as suffering from HIV, although this may be due mainly to poor detection methods in some economies. Malaria

More information

Use of high burden country lists for TB by WHO in the post-2015 era

Use of high burden country lists for TB by WHO in the post-2015 era Use of high burden country lists for TB by WHO in the post-2015 era Discussion paper initially prepared in April 2015 to facilitate feedback, and finalized after the June 2015 meeting of WHO s Strategic

More information

Frequently Asked Questions on Xpert MTB/RIF assay

Frequently Asked Questions on Xpert MTB/RIF assay Frequently Asked Questions on Xpert MTB/RIF assay Contents How does the test work?... 2 How was the Xpert MTB/RIF test developed?... 2 What is the public health significance?... 2 What does it cost?...

More information

The Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact

The Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact The Global Fund to Fight AIDS, Tuberculosis and Malaria Fourth Replenishment (2014-2016) Update on Results and Impact April 2013 Executive Summary Over the last five years, the results of Global Fund-supported

More information

The Role of the Health Service Administrator in TB Control. National Tuberculosis Control Programme

The Role of the Health Service Administrator in TB Control. National Tuberculosis Control Programme The Role of the Health Service Administrator in TB Control Goal/Objectives of NTP Mandate: To provide leadership for the health sector response to combat Tuberculosis in Ghana. Goal: To reduce the burden

More information

Doing the Math: The Dilemma of Drug Resistant Tuberculosis. Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012

Doing the Math: The Dilemma of Drug Resistant Tuberculosis. Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012 Doing the Math: The Dilemma of Drug Resistant Tuberculosis Frances Jamieson, MD, FRCPC PHO Rounds, April 17 th, 2012 Tuberculosis : A Global Problem WHO Estimates (2010 data): 8.8 million New Infections

More information

PRESS RELEASE WORLD POPULATION TO EXCEED 9 BILLION BY 2050:

PRESS RELEASE WORLD POPULATION TO EXCEED 9 BILLION BY 2050: PRESS RELEASE Embargoed until 12:00 PM, 11 March, 2009 WORLD POPULATION TO EXCEED 9 BILLION BY 2050: Developing Countries to Add 2.3 Billion Inhabitants with 1.1 Billion Aged Over 60 and 1.2 Billion of

More information

EVERY YEAR 9 MILLION PEOPLE GET SICK WITH TB. 3 MILLION DON T GET THE CARE THEY NEED. HELP US REACH THEM. LEAVE NO ONE BEHIND.

EVERY YEAR 9 MILLION PEOPLE GET SICK WITH TB. 3 MILLION DON T GET THE CARE THEY NEED. HELP US REACH THEM. LEAVE NO ONE BEHIND. EVERY YEAR 9 MILLION PEOPLE GET SICK WITH TB. 3 MILLION DON T GET THE CARE THEY NEED. HELP US REACH THEM. LEAVE NO ONE BEHIND. Help achieve zero deaths and put an end to the global TB epidemic. What does

More information

Eligibility List 2015

Eligibility List 2015 The Global Fund adopted an allocation-based approach for funding programs against HIV/AIDS, TB and malaria in 2013. The Global Fund policy states that countries can receive allocation only if their components

More information

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section

More information

Collaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO

Collaborative TB and HIV Services for Drug Users. Christian Gunneberg M.O. WHO Collaborative TB and HIV Services for Drug Users Christian Gunneberg M.O. WHO What I will address The problems of HIV/TB and Drug use. The policy guide. What next. Drug use and HIV Drug users are a large

More information

Out of Step Deadly implementation gaps. A survey of TB diagnostic and treatment practices in eight countries. October 2014. www.msfaccess.

Out of Step Deadly implementation gaps. A survey of TB diagnostic and treatment practices in eight countries. October 2014. www.msfaccess. Out of Step Deadly implementation gaps in the TB response A survey of TB diagnostic and treatment practices in eight countries October 2014 www.msfaccess.org About Médecins Sans Frontières (MSF) MSF is

More information

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

Global Update on HIV Treatment 2013: Results, Impact and Opportunities June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child

More information

Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014)

Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014) Definitions and reporting framework for tuberculosis 2013 revision (updated December 2014) Cover photos: WHO Photo Library Top, Nepal (C. Black); middle, Afghanistan (C. Black); bottom, China (S. Lim)

More information

Stronger health systems. Greater health impact.

Stronger health systems. Greater health impact. tuberculosis strengthening health systems to stop tb: a people-centered approach Stronger health systems. Greater health impact. strong skills and a caring heart A Kenyan Nurse Shows What It Takes to Manage

More information

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in

More information

Referral Guidelines for TB/HIV co-management. (First Edition)

Referral Guidelines for TB/HIV co-management. (First Edition) Referral Guidelines for TB/HIV co-management (First Edition) Government of Lesotho April 2011 1 REFERRAL GUIDELINES FOR TB/HIV CO-MANAGEMENT INTRODUCTION Many TB patients are infected with HIV. Many people

More information

General Information on Tuberculosis

General Information on Tuberculosis General Information on Tuberculosis ON THE MOVE AGAINST TUBERCULOSIS: Transforming the fi ght towards elimination World TB Day 2011 SAARC Tuberculosis & HIV/AIDS Centre GPO Box No 9517, Kathmandu, Nepal

More information

Tuberculosis OUR MISSION THE OPPORTUNITY

Tuberculosis OUR MISSION THE OPPORTUNITY Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is

More information

Integrated TB and HIV Public health laboratory Network. TB/HIV Program Dr. S. Marealle

Integrated TB and HIV Public health laboratory Network. TB/HIV Program Dr. S. Marealle Integrated TB and HIV Public health laboratory Network TB/HIV Program Dr. S. Marealle Epidemiological situation of TB 13140 cases of all forms of TB reported (2010) Incidence rate 635 per 100,000 population

More information

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0 Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan

More information

Technical FAQs on Hain Genotype MTBDRplus Line Probe Assay

Technical FAQs on Hain Genotype MTBDRplus Line Probe Assay What is the Hain Genotype MTBDRplus and how does it work? The Genotype MTBDRplus test is a WHO-endorsed line-probe assay (LPA) for the rapid detection of Mycobacterium tuberculosis complex (MTB) and mutations

More information

e-tb Manager: A Comprehensive Web-Based Tool for Programmatic Management

e-tb Manager: A Comprehensive Web-Based Tool for Programmatic Management e-tb Manager: A Comprehensive Web-Based Tool for Programmatic Management of TB and Drug-Resistant TB Management Sciences for Health Facts about TB* TB is contagious and airborne; each untreated person

More information

Introduction to the PPI

Introduction to the PPI Introduction to the PPI Training in the Key Concepts of the PPI A Grameen Foundation Product To enable the poor, especially the poorest, to create a world without poverty Progress out of Poverty Index

More information

Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010

Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010 Richard H. Needle, PhD, MPH Lin Zhao, PhD candidate (UCSF School of Nursing) CSIS Africa Program Roundtable June 10, 2010 Reference Group to the United Nations on HIV and Injecting Drug Use 2010 Mathers:

More information

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology

More information

International TB Standards & Strategies for Screening in Migrants. IOM Perspectives

International TB Standards & Strategies for Screening in Migrants. IOM Perspectives International TB Standards & Strategies for Screening in Migrants IOM Perspectives TB Screening for Migration A duality?...don t splash all over the mainstream media that immigrants have TB, it will just

More information

Protocol for the Control of Tuberculosis

Protocol for the Control of Tuberculosis Protocol QH-HSDPTL-040-1:2015 Effective Date: 11 November 2015 Review Date: 11 November 2018 Supersedes: Protocol QH-HSDPTL-040-1:2013 QH-HSDPTL-040-2:2013 QH-HSDPTL-040-3:2013 Health Service Directive

More information

2ND FORUM OF NATIONAL STOP TB PARTNERSHIP IN SOUTH EAST ASIA, WEST PACIFIC AND EAST MEDITERRANEAN REGIONS 3 4 MARCH 2014 - JAKARTA, INDONESIA

2ND FORUM OF NATIONAL STOP TB PARTNERSHIP IN SOUTH EAST ASIA, WEST PACIFIC AND EAST MEDITERRANEAN REGIONS 3 4 MARCH 2014 - JAKARTA, INDONESIA 2ND FORUM OF NATIONAL STOP TB PARTNERSHIP IN SOUTH EAST ASIA, WEST PACIFIC AND EAST MEDITERRANEAN REGIONS 3 4 MARCH 2014 - JAKARTA, INDONESIA The Stop TB Partnership Indonesia is a partnership group comprising

More information

Guidance on how to measure contributions of public-private mix to TB control

Guidance on how to measure contributions of public-private mix to TB control Guidance on how to measure contributions of public-private mix to TB control Project report to the Tuberculosis Control Assistance Programme (TB CAP) Project number: APA4, C3-01 The World Health Organization

More information

A Comprehensive Global Public Health

A Comprehensive Global Public Health A Comprehensive Global Public Health Strategy & Engaging the Supply Chain Dr. Rick Wilkins March, 2009 2009 Chevron Corporation Global Public Health HIV/AIDS, Tuberculosis, and Malaria Attention to these

More information

AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR

AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR Update on progress to implement the African Union Roadmap on Shared Responsibility and Global Solidarity for AIDS, TB and Malaria Response in Africa (2012

More information

TB Case Definitions Revision May 2011

TB Case Definitions Revision May 2011 TB Case Definitions Revision May 2011 Table of contents TABLE OF CONTENTS 1 1. BACKGROUND 3 2. CURRENT WHO DEFINITIONS OF CASES AND TREATMENT OUTCOMES 4 3. COMMENTARY ON CURRENT WHO DEFINITIONS OF CASES

More information

UPDATE UNAIDS 2016 DATE 2016

UPDATE UNAIDS 2016 DATE 2016 GLOBAL AIDS UP GLOBAL AIDS UPDATE UNAIDS 2016 DATE 2016 ENORMOUS GAINS, PERSISTENT CHALLENGES The world has committed to ending the AIDS epidemic by 2030. How to reach this bold target within the Sustainable

More information

Progress out of Poverty Index as an effective and efficient tool for. Results Measurement

Progress out of Poverty Index as an effective and efficient tool for. Results Measurement Progress out of Poverty Index as an effective and efficient tool for Results Measurement A presentation to DCED Participants March 24-26, 2014, Bangkok, Thailand Presentation Outline Introduction of Grameen

More information

Treatment of tuberculosis. guidelines. Fourth edition

Treatment of tuberculosis. guidelines. Fourth edition Treatment of tuberculosis guidelines Fourth edition Treatment of tuberculosis Guidelines Fourth edition WHO Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines 4th ed. WHO/HTM/TB/2009.420

More information

The Platform. for. Human Resource Development for TB. Five years exchange of global experience

The Platform. for. Human Resource Development for TB. Five years exchange of global experience The Platform for Human Resource Development for TB Five years exchange of global experience 1 The Global Health Bureau, Office of Health, Infectious Disease and Nutrition (HIDN), US Agency for International

More information

Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET

Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global

More information

CHANGES TO BERMUDA WORK PERMIT POLICIES EFFECTIVE DECEMBER 2014

CHANGES TO BERMUDA WORK PERMIT POLICIES EFFECTIVE DECEMBER 2014 CHANGES TO BERMUDA WORK PERMIT POLICIES EFFECTIVE DECEMBER 2014 Bermuda s Ministry of Home Affairs issued for consultation in October 2014 proposed changes to the Work Permit Policy to be made effective

More information

RESCINDED. 3. Process for the Diagnosis and Treatment of Tuberculosis

RESCINDED. 3. Process for the Diagnosis and Treatment of Tuberculosis Protocol Effective Date: 01 July 2013 Review Date: 01 July 2016 Supersedes: New Protocol Health Service Directive Tuberculosis Management Protocol for the Treatment of Tuberculosis 1. Purpose This protocol

More information

Time to act Save a million lives by 2015 Prevent and treat tuberculosis among people living with HIV

Time to act Save a million lives by 2015 Prevent and treat tuberculosis among people living with HIV Time to act Save a million lives by 2015 Prevent and treat tuberculosis among people living with HIV Living with HIV, dying from tuberculosis A THIEF IN OUR MIDST We live in a time of unprecedented hope

More information

Scientific Facts on. Malaria. status & challenges of the epidemic

Scientific Facts on. Malaria. status & challenges of the epidemic page 1/8 Scientific Facts on Malaria status & challenges of the epidemic Source document: WHO (2008) Summary & Details: GreenFacts Context - Malaria is one of the most common infectious diseases and a

More information

Session 4: The Drug Management Cycle: Selection. David Peters

Session 4: The Drug Management Cycle: Selection. David Peters This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Global Public Health Internship at UNAIDS, Geneva, Switzerland. Elsie Essien Victoria Rodriguez

Global Public Health Internship at UNAIDS, Geneva, Switzerland. Elsie Essien Victoria Rodriguez Global Public Health Internship at UNAIDS, Geneva, Switzerland Elsie Essien Victoria Rodriguez Duke University Program on Global Policy and Governance in Geneva, Switzerland Four tracks: Global Health

More information

Tuberculosis in the Americas

Tuberculosis in the Americas CHAPTER 1. The Regional Burden of tuberculosis A Tuberculosis in the Americas Regional Report 2012 Epidemiology, Control and Financing Regional Report 2012 Epidemiology, Control and Financing Tuberculosis

More information

Goal 5: Improve Maternal Health

Goal 5: Improve Maternal Health 107 In the Asia and Pacific region, maternal mortality ranges from 1 per 100,000 live births in Hong Kong, China to 1,800 in Afghanistan. The People s Republic of China (PRC) has a rather low rate of 45

More information

Summary and Key Points

Summary and Key Points Summary and Key Points The World Malaria Report 2011 summarizes information received from 106 malaria-endemic countries and other sources and updates the analyses presented in the 2010 report. It highlights

More information

Management of Tuberculosis: Indian Guidelines

Management of Tuberculosis: Indian Guidelines Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the

More information

Chapter 3 South African guidelines and introduction to clinical cases

Chapter 3 South African guidelines and introduction to clinical cases Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment

More information

Countries Ranked by Per Capita Income A. IBRD Only 1 Category iv (over $7,185)

Countries Ranked by Per Capita Income A. IBRD Only 1 Category iv (over $7,185) Page 1 of 5 Note: This OP 3.10, Annex C replaces the version dated September 2013. The revised terms are effective for all loans that are approved on or after July 1, 2014. Countries Ranked by Per Capita

More information

Principles and Structure of a Research Protocol. The Union, Paris, France MSF, Brussels, Belgium

Principles and Structure of a Research Protocol. The Union, Paris, France MSF, Brussels, Belgium Principles and Structure of a Research Protocol The Union, Paris, France MSF, Brussels, Belgium BASIC STRUCTURE Background and rationale to study Aim and objectives (the research question) Methods (includes

More information

TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS

TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS TREATING DRUG-SENSITIVE TB IN INDIA: IMPLEMENTATION OF DAILY THERAPY WITH FIXED DOSE COMBINATIONS Policy brief, March 2015 Tuberculosis (TB), a communicable disease that affects 9 million people worldwide,

More information

Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment

Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Tuberculosis Airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tb) M. tb complex (MTBC) includes

More information

DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014

DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014 DRUG-RESISTANT TB SURVEILLANCE & RESPONSE SUPPLEMENT GLOBAL TUBERCULOSIS REPORT 2014 World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the

More information

Diagnostic Network & Treatment Strengthening Strategies in USAID-Priority Countries

Diagnostic Network & Treatment Strengthening Strategies in USAID-Priority Countries Diagnostic Network & Treatment Strengthening Strategies in USAID-Priority Countries Amy Piatek (on behalf of) USAID/Global Health Bureau Washington DC April 29, 2015 The United States Government Lantos-Hyde

More information

Millennium Development Goal 2 Global Education Scorecard: Who s on target?

Millennium Development Goal 2 Global Education Scorecard: Who s on target? Millennium Development Goal 2 Global Scorecard: Who s on target? However, 59 million children remain out of the classroom, donor resources for basic education continue to decline and too many countries

More information

Tuberculosis Quiz. Accelerating Advocacy for TB/HIV 15th July 2010, Vienna

Tuberculosis Quiz. Accelerating Advocacy for TB/HIV 15th July 2010, Vienna Tuberculosis Quiz Accelerating Advocacy for TB/HIV 15th July 2010, Vienna Tuberculosis (TB) is caused by a virus? TRUE FALSE Tuberculosis (TB) is caused by a virus? FALSE Tuberculosis Caused by infection

More information

Proforma Cost for international UN Volunteers for UN Partner Agencies for 2016. International UN Volunteers (12 months)

Proforma Cost for international UN Volunteers for UN Partner Agencies for 2016. International UN Volunteers (12 months) Proforma Cost for international UN Volunteers for UN Partner Agencies for 2016 Country Of Assignment International UN Volunteers (12 months) International UN Youth Volunteers (12 months) University Volunteers

More information

Tuberculosis Prevention and Control Protocol, 2008

Tuberculosis Prevention and Control Protocol, 2008 Tuberculosis Prevention and Control Protocol, 2008 Preamble The Ontario Public Health Standards (OPHS) are published by the Minister of Health and Long- Term Care under the authority of the Health Protection

More information

DRINKINGWATERCOVERAGE

DRINKINGWATERCOVERAGE DRINKINGWATERCOVERAGE I n 2002, 83 per cent of the world s population around 5.2 billion people used improved drinking water sources. These include piped water connections and standpipes, as described

More information

COVER: 4-year-old Jan Carlos jumps on his parents bed. The family reported a significant drop in the number of malaria cases since

COVER: 4-year-old Jan Carlos jumps on his parents bed. The family reported a significant drop in the number of malaria cases since Results Report 215 COVER: 4-year-old Jan Carlos jumps on his parents bed. The family reported a significant drop in the number of malaria cases since insecticide-treated nets were distributed two years

More information

TB preventive therapy in children. Introduction

TB preventive therapy in children. Introduction TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are

More information

World Health Organization Department of Communicable Disease Surveillance and Response

World Health Organization Department of Communicable Disease Surveillance and Response WHO/CDS/CSR/ISR/2000.1 WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases World Health Organization Department of Communicable Disease Surveillance and Response This document has been

More information

Year 1. Annual Report. October 1, 2014 September 30, 2015

Year 1. Annual Report. October 1, 2014 September 30, 2015 Challenge TB - Malawi Year Annual Report October, 204 September 30, 205 October 30, 205 This report was made possible through the support for Challenge TB provided by the United States Agency for International

More information

Expression of Interest in Research Grant Applications

Expression of Interest in Research Grant Applications INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY THE ACADEMY OF SCIENCES FOR THE DEVELOPING WORLD UNITED NATIONS EDUCATIONAL, SCIENTIFIC AND CULTURAL ORGANIZATION ICGEB-TWAS-UNESCO/IBSP Joint

More information

Living with HIV, Dying of TB A Critique of the Response of Global AIDS Donors to the Co-epidemic

Living with HIV, Dying of TB A Critique of the Response of Global AIDS Donors to the Co-epidemic Living with HIV, Dying of TB A Critique of the Response of Global AIDS Donors to the Co-epidemic Advocacy to Control Tuberculosis Internationally (ACTION) March 2009 Advocacy to Control Tuberculosis Internationally

More information

DISCLAIMER. www.health.gov.fj

DISCLAIMER. www.health.gov.fj DISCLAIMER The authors do not warrant the accuracy of the information contained in the TB Technical Guideline and do not take responsibility for any death, loss, damage or injury caused by using the information

More information

TB-HIV Co-Infection in Children. Reené Naidoo Paediatric HIV/TB Symposium August 2013

TB-HIV Co-Infection in Children. Reené Naidoo Paediatric HIV/TB Symposium August 2013 TB-HIV Co-Infection in Children Reené Naidoo Paediatric HIV/TB Symposium August 2013 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children in South Africa HIV infection

More information

Scenario for Vegetable Oil Fortification with Vitamin A in 75 Countries

Scenario for Vegetable Oil Fortification with Vitamin A in 75 Countries Scenario for Vegetable Oil Fortification with Vitamin A in 75 Countries What if All vegetable oil consumed in 75 countries included in DARs for which FAO data is available were fortified to a level of

More information

U.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening

U.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening U.S. President s Malaria Initiative (PMI) Approach to Health Systems Strengthening What is Health System Strengthening? Strengthening health systems means supporting equitable and efficient delivery of

More information

Principles for the Management of Tuberculosis in New South Wales

Principles for the Management of Tuberculosis in New South Wales Policy Directive Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/

More information

Laboratory Considerations for Use of Cepheid Xpert MTB/RIF Assay

Laboratory Considerations for Use of Cepheid Xpert MTB/RIF Assay Fact sheet: cepheid xpert mtb/rif assay November 2013 Laboratory Considerations for Use of Cepheid Xpert MTB/RIF Assay This document is intended to guide laboratories on integrating the Cepheid Xpert MTB/RIF

More information

Contents. 1. Overview of AIPN 2. Access to Dossier Information 3. Access to Patent Family and Legal Status 4. Demonstration 5.

Contents. 1. Overview of AIPN 2. Access to Dossier Information 3. Access to Patent Family and Legal Status 4. Demonstration 5. Contents 1. Overview of AIPN 2. Access to Dossier Information 3. Access to Patent Family and Legal Status 4. Demonstration 5. Exercises 1 What is AIPN? AIPN is the Web based Service only for Examiners

More information

Entrance Health Certificate

Entrance Health Certificate Entrance Health Certificate 1 Wheelock College Student Health Service ENTRANCE HEALTH CERTIFICATE The Entrance Health Certificate must be completed in its entirety and brought with you to Boston. Admission

More information

THAILAND. 1. Market Trends: Import Opportunities and Consumption. Items 2002 2006 Change in % Major Markets in %

THAILAND. 1. Market Trends: Import Opportunities and Consumption. Items 2002 2006 Change in % Major Markets in % THAILAND A. MARKET FOR FRESH FRUITS & VEGETABLES 1. Market Trends: Import Opportunities and Consumption Items 2002 2006 Change in % Major Markets in % Value Quantity Value Quantity Value Quantity $'000

More information

No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER 5 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008

No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER 5 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008 COUNCIL OF THE EUROPEAN UNION Brussels, 22 May 2008 9637/08 SAN 88 DENLEG 52 VETER 7 NOTE from: Committee of Permanent Representatives (Part 1) to: Council No. prev. doc.: 9392/08 SAN 77 DENLEG 48 VETER

More information

Brain Drain and Brain Gain: Selected Country Experiences and Responses

Brain Drain and Brain Gain: Selected Country Experiences and Responses Brain Drain and Brain Gain: Selected Country Experiences and Responses Manuel M. Dayrit MD, MSc Dean, Ateneo School of Medicine and Public Health Manila, Philippines manuel_m_dayrit@yahoo.com Australia,

More information

UNAIDS World AIDS Day Report 2012

UNAIDS World AIDS Day Report 2012 UNAIDS World AIDS Day Report 212 Results 1 Foreword The sun finds a way to shine into even the deepest parts of the forest. It is a metaphor for all of us who are working to restore hope and dignity around

More information

TB & HIV co infection interactions, considerations, pitfalls. Dr Sindisiwe van Zyl

TB & HIV co infection interactions, considerations, pitfalls. Dr Sindisiwe van Zyl TB & HIV co infection interactions, considerations, pitfalls Dr Sindisiwe van Zyl Background facing a double epidemic TB leads to HIV disease progression & vice versa 70% TB patients are HIV co infected

More information

Ensuring an Effective Continuum of Response and Cascade of Care for Persons Living with HIV in Uganda

Ensuring an Effective Continuum of Response and Cascade of Care for Persons Living with HIV in Uganda Ensuring an Effective Continuum of Response and Cascade of Care for Persons Living with HIV in Uganda From HIV testing to prevention and treatment The primary goal of the Continuum of Response (COR) approach

More information

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background

More information

United Kingdom Human Trafficking Centre National Referral Mechanism Statistics 2013

United Kingdom Human Trafficking Centre National Referral Mechanism Statistics 2013 United Kingdom Human Trafficking Centre National Referral Mechanism Statistics 2013 Date 20/01/2014 Version number V1.0 NRM Statistics 2013 1 NOT PROTECTIVELY MARKED In 2013 the UK National Referral Mechanism

More information

Transforming the Fight

Transforming the Fight Contents Transforming the Fight TOWARDS ELIMINATION OF TUBERCULOSIS - Guiding Principle - Key Messages - Where are we (Current Situation) Control Interventions World TB Day 24 March 1884 Agent Individual

More information

Diagnosis of PTB, EPTB and MDR-TB

Diagnosis of PTB, EPTB and MDR-TB Diagnosis of PTB, EPTB and MDR-TB Prof. Madhukar Pai, MD, PhD Director, McGill Global Health Programs Associate Director, McGill International TB Centre, Canada madhukar.pai@mcgill.ca 1 Conflicts of interest

More information

FDI performance and potential rankings. Astrit Sulstarova Division on Investment and Enterprise UNCTAD

FDI performance and potential rankings. Astrit Sulstarova Division on Investment and Enterprise UNCTAD FDI performance and potential rankings Astrit Sulstarova Division on Investment and Enterprise UNCTAD FDI perfomance index The Inward FDI Performance Index ranks countries by the FDI they receive relative

More information

Status of ratification of the United Nations Convention against Corruption as at 30 September 2011

Status of ratification of the United Nations Convention against Corruption as at 30 September 2011 3 October 2011 English only Conference of the States Parties to the United Nations Convention against Corruption Fourth session Marrakech, Morocco, 24-28 October 2011 Agenda item 2 of the provisional agenda

More information

THE GAP REPORT UNAIDS

THE GAP REPORT UNAIDS THE GAP REPORT UNAIDS 1 Our mission is to build a better world. To leave no one behind. To stand for the poorest and the most vulnerable in the name of global peace and social justice. Ban Ki-moon United

More information

Summary of GAVI Alliance Investments in Immunization Coverage Data Quality

Summary of GAVI Alliance Investments in Immunization Coverage Data Quality Summary of GAVI Alliance Investments in Immunization Coverage Data Quality The GAVI Alliance strategy and business plan for 2013-2014 includes a range of activities related to the assessment and improvement

More information

Facilitating Economic Integration in Asia-Pacific through Aid for Trade. 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio

Facilitating Economic Integration in Asia-Pacific through Aid for Trade. 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio Facilitating Economic Integration in Asia-Pacific through Aid for Trade 23 April 2014 // Tunis Mia Mikic Teemu Alexander Puutio ODA finally on the rebound Globally development aid rose by 6.1% in real

More information